New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?

Author： Kallen K-J. Galle P.R. Rose-John S.

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.9, 1999-09, pp. : 1327-1349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Personalized therapy in pain management: where do we stand?

By Stamer Ulrike M Zhang Lan Stüber Frank

Pharmacogenomics, Vol. 11, Iss. 6, 2010-06 ,pp. : 843-864

Future Medicine

Access to resources Recommend Favorite

Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?

Current Medicinal Chemistry, Vol. 16, Iss. 22, 2009-08 ,pp. : 2824-2838

Bentham Science Publishers

Access to resources Recommend Favorite

Statins in Heart Failure—Where Do We Stand?

By Lyons Kristopher McVeigh Gary Harbinson Mark

Cardiovascular Drugs and Therapy, Vol. 25, Iss. 1, 2011-02 ,pp. : 99-104

Springer Publishing Company

Access to resources Recommend Favorite

Intelligent use of NSAIDs - where do we stand?

By Berger R.G.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 19-30

Informa Healthcare

Access to resources Recommend Favorite

Mucosal Vaccines: Where Do We Stand?

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 20, 2013-10 ,pp. : 2609-2628

Bentham Science Publishers

Access to resources Recommend Favorite